Dr Lal Pathlabs Q1 FY27 Results (NSE: LALPATHLAB)
Signal: Margin expansion
The read
Dr. Lal PathLabs delivered a standout quarter with revenue accelerating to 19.1% YoY (highest in 4 years) driven by robust volume growth. EBITDA margin expanded 230bps to 31.0% on operating leverage and cost control, reversing the contraction seen in Q4FY26. PAT grew 27.2% to ₹170 Cr, and the strong cash position (₹1,693 Cr) provides strategic flexibility for M&A. The trajectory supports sustained profitable growth.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹798 Cr | 19.1% | 13.5% |
| EBIT | ₹247 Cr | 28.7% | |
| Net profit | ₹170 Cr | 27.2% | |
| EPS | ₹10.1 | 27.8% | |
| EBIT margin | 31.0% |
P&L walk
Revenue grew 19.1% YoY to ₹798 Cr, the highest quarterly growth in 4 years, driven by volume (samples +7.9%, patients +10.7%) and favourable mix. EBITDA margin expanded 230bps to 31.0% on operating leverage and cost control (employee cost down 1.8pp as % of revenue). PAT up 27.2% to ₹170 Cr, with other income contributing ₹32 Cr (13% of EBITDA). EPS ₹10.1 (+27.8%).
Key positives
- Highest quarterly revenue growth in 4 years at 19.1% YoY, volume-led (samples +7.9%, patients +10.7%).
- EBITDA margin expanded 230bps YoY to 31.0% due to operating leverage and cost efficiencies.
- PAT up 27.2% to ₹170 Cr, EPS up 27.8% to ₹10.1.
- ROCE (excl. cash) improved to 58% from 44% in FY26, reflecting strong capital efficiency.
- Cash and cash equivalents at ₹1,693 Cr provide ample firepower for inorganic growth.
Key concerns
- Other income of ₹32 Cr accounted for 13% of EBITDA; reliance on non-operating income could mask core earnings weakness in adverse conditions.
- Depreciation grew 25.7% YoY, outpacing revenue growth, indicating ongoing capex intensity.
Research and educational content only. Not investment advice.